Related references
Note: Only part of the references are listed.Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S. Popat et al.
ANNALS OF ONCOLOGY (2022)
ASO Visual Abstract: Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study
Vahan Kepenekian et al.
ANNALS OF SURGICAL ONCOLOGY (2022)
Survival Outcomes for Malignant Peritoneal Mesothelioma at Academic Versus Community Hospitals
Vanessa M. Welten et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2022)
Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy
Michael G. White et al.
BRITISH JOURNAL OF CANCER (2021)
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas et al.
LANCET (2021)
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
Dean A. Fennell et al.
LANCET ONCOLOGY (2021)
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
Kanwal Raghav et al.
CANCER DISCOVERY (2021)
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab
Prasad S. Adusumilli et al.
CANCER DISCOVERY (2021)
The Safety of Iterative Cytoreductive Surgery and HIPEC for Peritoneal Carcinomatosis: A High Volume Center Prospectively Maintained Database Analysis
Eliahu Bekhor et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Predictors and Outcomes of Surgery in Peritoneal Mesothelioma: an Analysis of 2000 Patients from the National Cancer Database
Lana Bijelic et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative
David Roife et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
Nadine L. de Boer et al.
BMJ OPEN (2019)
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Michele Carbone et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma Phase 1b Results From the JAVELIN Solid Tumor Trial
Raffit Hassan et al.
JAMA ONCOLOGY (2019)
Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study
Brice Malgras et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group
Aliya Noor Husain et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking
Samer A. Naffouje et al.
MEDICAL ONCOLOGY (2018)
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas
Noemie Leblay et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Yue C. Li et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database Multi-Institutional Retrospective Study
V. Kepenekian et al.
EUROPEAN JOURNAL OF CANCER (2016)
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis
Joseph H. Helm et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent or Progressive Diffuse Malignant Peritoneal Mesothelioma: Clinicopathologic Characteristics and Survival Outcome
Chukwuemeka Ihemelandu et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Current Trends in the Management of Malignant Peritoneal Mesothelioma
John T. Miura et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients
Sandy Liu et al.
PATHOLOGY (2014)
A Novel Nomogram for Peritoneal Mesothelioma Predicts Survival
Nicholas P. Schaub et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Diffuse malignant peritoneal mesothelioma: Long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC)
Dario Baratti et al.
EUROPEAN JOURNAL OF CANCER (2013)
Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma
H. Richard Alexander et al.
SURGERY (2013)
Cytoreductive Surgery with Selective Versus Complete Parietal Peritonectomy Followed by Hyperthermic Intraperitoneal Chemotherapy in Patients with Diffuse Malignant Peritoneal Mesothelioma: A Controlled Study
Dario Baratti et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Germline BAP1 mutations predispose to malignant mesothelioma
Joseph R. Testa et al.
NATURE GENETICS (2011)
Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Malignant Peritoneal Mesothelioma: Mitomycin Versus Cisplatin
Aaron U. Blackham et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience
Tristan D. Yan et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma:: Final report of a phase II trial
George R. Simon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center
Niraj J. Gusani et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference
R. Hassan et al.
ANNALS OF ONCOLOGY (2006)
Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma:: Outcomes of an expanded access program
Pasi A. Jaenne et al.
CLINICAL LUNG CANCER (2005)
Share Paper
